Catalyst Dossier · compiled by CeliA 🧫

Genmab A/S (GMAB)

Pharmaceutical Preparations · market cap $15.7B · as of 2026-07-10

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-03-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Genmab A/S (GMAB) is a Danish antibody-focused biotech trading at ~$29.54 with a market cap of ~$15.7B, operating across oncology indications through a broad pipeline that spans multiple Phase 2 and Phase 3 programs. The company's most clinically advanced proprietary asset is epcoritamab, a bispecific antibody in Phase 3 for diffuse large B-cell lymphoma (DLBCL), with a cluster of high-importance readouts expected through mid-2027. A mixed Phase 3 result was reported in June 2026, introducing uncertainty into the near-term catalyst stack.

The catalyst path

2027-03-15 (est.)Phase 2 · Epcoritamabimp 7/10
2027-06-15 (est.)Phase 3 · Epcoritamabimp 9/10

Pipeline

Asset	Phase	Indication
gemcitabine and oxaliplatin	Phase 2	Diffuse Large B-Cell Lymphoma
GEN1042	Phase 2	Malignant Solid Tumor
tisotumab vedotin	Phase 2	Solid Tumor
Zalutumumab	Phase 3	Head and Neck Cancer
Epcoritamab	Phase 3	Diffuse Large B-Cell Lymphoma
Epcoritamab (monotherapy)	Phase 2	Diffuse Large B Cell Lymphoma
Rina-S	Phase 3	Endometrial Cancer
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.	Phase 2	Breast Cancer, Breast Neoplasms
Enapotamab vedotin (HuMax-AXL-ADC)	Phase 2	Ovarian Cancer
Investigator's Choice Chemotherapy	Phase 3	Diffuse Large B-Cell Lymphoma
Acasunlimab	Phase 3	Cutaneous Melanoma
GEN1286	Phase 2	Advanced Solid Tumor
Acasunlimab in combination with docetaxel (in a single expansion cohort)	Phase 2	Solid Tumors
HuMax-CD4	Phase 2	Cutaneous T-Cell Lymphoma

Price & technical context

3-month

+6.3%

6-month

-11.4%

12-month

+36.0%

52-wk range

$21.08–$35.34

vs 50-day MA

+7.7%

vs 200-day MA

+0.9%

Realized vol

46.3%

Max drawdown

-36.9%

Daily closes through 2026-08-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GMAB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.